The Patent Finder

Human ANTI-B7RP1 Neutralizing Antibodies

E R Squibb and Sons LLC

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application 60/700,265, filed Jul 18, 2005. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 10,072,090Human Anti-B7RP1 Neutralizing Antibodies
In force
 · High confidence
Amgen Inc.In force
High confidence
US 7,868,140Human ANTI-B7RP1 Neutralizing Antibodies
In force
 · High confidence
E. R. Squibb & Sons, L.L.C.In force
High confidence
US 8,981,071Human anti-B7RP1 Neutralizing Antibodies
In force
 · High confidence
E. R. Squibb & Sons, L.L.C.In force
High confidence
US 9,266,945Human Anti-B7RP1 Neutralizing Antibodies
Term ended
Ended no later than Jul 18, 2026 · Medium confidence
E. R. Squibb & Sons, L.L.C.Term endedEnded no later than Jul 18, 2026
Medium confidence
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by E R Squibb and Sons LLC.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited